English Journal
- Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
- Jaglowski SM1, Jones JA1, Nagar V2, Flynn JM1, Andritsos LA1, Maddocks KJ1, Woyach JA1, Blum KA1, Grever MR1, Smucker K1, Ruppert AS1, Heerema NA3, Lozanski G3, Stefanos M1, Munneke B4, West JS4, Neuenburg JK4, James DF4, Hall N2, Johnson AJ1, Byrd JC1.
- Blood.Blood.2015 Aug 13;126(7):842-50. doi: 10.1182/blood-2014-12-617522. Epub 2015 Jun 26.
- Ibrutinib represents a therapeutic advance in chronic lymphocytic leukemia (CLL) but as monotherapy produces few complete remissions in previously treated patients. Anti-CD20 antibodies have improved response and progression-free survival (PFS) when combined with chemotherapy. We evaluated the safet
- PMID 26116658
- The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis.
- Li J1,2,3, Li S4, Chen R5,6,7, Yu H8, Lu X9,10,11,12.
- Journal of ovarian research.J Ovarian Res.2015 Aug 6;8:54. doi: 10.1186/s13048-015-0181-z.
- OBJECTIVE: The prognostic value of anti-angiogenesis therapy in ovarian cancer patients is currently under debate. In this study, we assessed the effects of anti-angiogenesis therapy on the progression free survival (PFS) and overall survival (OS) of ovarian cancer patients.MATERIALS AND METHODS: Pu
- PMID 26242216
- Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.
- Dussol AS1, Joly MO2,3,4, Vercherat C2, Forestier J1, Hervieu V2,3,4, Scoazec JY2,3,4, Lombard-Bohas C1, Walter T1,2,4.
- Cancer.Cancer.2015 Jun 8. doi: 10.1002/cncr.29517. [Epub ahead of print]
- BACKGROUND: The alkylating agents (ALKYs) streptozotocin, dacarbazine, and temozolomide currently are the main drugs used in systemic chemotherapy for neuroendocrine tumors (NETs). The promising activity shown by gemcitabine and oxaliplatin (GEMOX) in previous studies prompted this study 1) to confi
- PMID 26058464
Japanese Journal
- フッ素系界面活性剤の水環境汚染の現況と今後の展望
- 村上 道夫,滝沢 智
- Journal of Japan Society on Water Environment 33(8), 103-114, 2010
- … Perfluorinated surfactants (PFSs) such as perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) have been detected worldwide in surface water, groundwater, seawater, drinking water and aquatic organisms. … Concerns and interests about PFSs in water environments are rapidly increasing. … Thus, management and risk control of PFS homologues including longer-chain PFSs such as PFNA are now required. …
- NAID 130000307316
- PFSs/PFAsのサンプル前処理および分析法について (マテリアルスポット:セミナーレビュー アメリカでの問題発祥から,今ゴールに向けて--技術情報協会「セミナー+分析ラボ見学レビュー」 PFOS/PFOAの最新動向と新規代替材料の開発・分析)
- 佐々木 俊哉
- マテリアルステージ 8(3), 115-124, 2008-06
- NAID 40016109202
Related Links
- パナソニック ファクトリーソリューションズ蘇州有限公司（PFSS） 中国 蘇州 環境パフォーマンスデータ パナソニック エコリレー・フォー・サステイナブル・アース エコリレー活動 パナソニックグループの<エコリレー活動>と ...
- RBRVS HCPCS CPT RVU HMO PPO. PFSS (Physicians Fee Schedule Software) is the best way for physicians, health care consultants, managed care HMOs, PPOs, reimbursement experts and consultants to create fee ...
Related Pictures
★リンクテーブル★
| 関連記事 | 「PFS」「PF」 |
「PFS」
[★] 無増悪生存期間 progression free survival